Physician profile
Travis S Lam
NPI 1841313020
$3,198.97
in general payments reported to CMS, 2019-2025
21 companies · $796 in 2025
The $796 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $433 · 2020: $69.58 · 2021: $106 · 2022: $64.63 · 2023: $597 · 2024: $1,132 · 2025: $796.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,330 · Education: $195.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,330.48 |
| Education | $194.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $913.47 | 2019-2025 | |
| Janssen Biotech, INC. | $464.69 | 2022-2024 | Tremfya |
| Ucb, INC. | $228.45 | 2019-2025 | Bimzelx |
| Sun Pharmaceutical Industries INC. | $209.08 | 2023-2025 | Ilumya |
| Genzyme Corporation | $188.73 | 2021-2025 | |
| Dermavant Sciences, INC. | $165.98 | 2024 | Vtama |
| Regeneron Healthcare Solutions, INC. | $154.59 | 2021-2025 | Libtayo, Dupixent |
| Arcutis Biotherapeutics, INC. | $145.72 | 2023-2025 | Zoryve |
| Lilly USA, LLC | $115.55 | 2023-2025 | Taltz, Ebglyss, Olumiant |
| Incyte Corporation | $110.32 | 2023-2025 | Opzelura |
| Novartis Pharmaceuticals Corporation | $109.44 | 2019-2025 | |
| Organon LLC | $84.75 | 2025 | Vtama |
| Pfizer INC. | $80.34 | 2023-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $75.15 | 2023-2025 | Jublia |
| Merck Sharp & Dohme LLC | $40.00 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $33.47 | 2019-2024 | Otezla |
| Genentech USA, INC. | $20.03 | 2019 | |
| Sanofi-Aventis U.S. LLC | $16.98 | 2019 | |
| Almirall LLC | $16.76 | 2025 | Klisyri |
| Botanix Sb INC | $14.40 | 2025 | Sofdra |
| Dusa Pharmaceuticals, INC. | $11.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Travis Lam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.